Holen Sie sich die Stockscreener-App
22.24
3.14%
-0.72
Handel nachbörslich:
22.68
0.44
+1.98%
Schlusskurs vom Vortag:
$22.96
Offen:
$22.92
24-Stunden-Volumen:
655.03K
Relative Volume:
0.52
Marktkapitalisierung:
$2.79B
Einnahmen:
$247.00M
Nettoeinkommen (Verlust:
$-353.00M
KGV:
-6.7388
EPS:
-3.3003
Netto-Cashflow:
$-484.00M
1W Leistung:
+7.70%
1M Leistung:
+0.59%
6M Leistung:
+53.59%
1J Leistung:
+223.73%
1-Tages-Spanne:
$22.15
$23.17
1-Wochen-Bereich:
$21.24
$23.45
52-Wochen-Spanne:
$6.50
$26.40
Arcus Biosciences Inc Stock (RCUS) Company Profile
Firmenname
Arcus Biosciences Inc
Sektor
Branche
Telefon
(510) 694-6200
Adresse
3928 POINT EDEN WAY, HAYWARD, CA
Compare RCUS vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
22.24 | 2.88B | 247.00M | -353.00M | -484.00M | -3.3003 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-12 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2026-01-13 | Hochstufung | Goldman | Neutral → Buy |
| 2026-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-02-26 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-10-21 | Eingeleitet | H.C. Wainwright | Neutral |
| 2024-10-08 | Eingeleitet | Wells Fargo | Overweight |
| 2022-11-18 | Eingeleitet | BofA Securities | Neutral |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2020-11-24 | Eingeleitet | Berenberg | Buy |
| 2020-11-23 | Eingeleitet | Evercore ISI | Outperform |
| 2020-04-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-09-27 | Eingeleitet | Mizuho | Buy |
| 2019-05-24 | Fortgesetzt | Citigroup | Buy |
| 2018-10-09 | Eingeleitet | Wedbush | Outperform |
| 2018-04-09 | Eingeleitet | Citigroup | Buy |
| 2018-04-09 | Eingeleitet | Goldman | Neutral |
| 2018-04-09 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Arcus Biosciences Inc Aktie (RCUS) Neueste Nachrichten
Pharma News: Can Arcus Biosciences Inc keep up with sector leadersQuarterly Investment Review & Community Consensus Trade Signals - baoquankhu1.vn
Citigroup Maintains Arcus Biosciences (RCUS) Buy Recommendation - MSN
RCUS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Arcus Biosciences, Inc. (RCUS) Stock forecasts - Yahoo Finance UK
Arcus Biosciences (NYSE:RCUS) Trading 5.4% Higher Following Analyst Upgrade - marketbeat.com
RCUS: Wedbush Raises Price Target for Arcus Biosciences | RCUS S - GuruFocus
Arcus Biosciences (NYSE:RCUS) Price Target Raised to $41.00 - MarketBeat
RCUS Technical Analysis & Stock Price Forecast - Intellectia AI
Gainers Report: Will Arcus Biosciences Inc stock benefit from M A2026 Breakouts & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Arcus Biosciences, Inc. (RCUS) Stock Forecasts - Yahoo Finance
Behavioral Patterns of RCUS and Institutional Flows - Stock Traders Daily
Insider Trends: Is Arcus Biosciences Inc still a buy after recent gains2026 Retail Activity & Real-Time Volume Analysis Alerts - baoquankhu1.vn
RCUS Price History for Arcus Biosciences Stock - Barchart.com
Arcus Biosciences (RCUS) Vanguard shows 0 shares after Jan 12, 2026 realignment - Stock Titan
Arcus Biosciences (NYSE:RCUS) Upgraded at Truist Financial - MarketBeat
Arcus Biosciences, Inc. (NYSE:RCUS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Arcus Executives Offload Shares Amid Surge in Hiring—A "Pump and Dump" Warning Sign for RCUS - Bitget
Two new hires get Arcus stock awards priced at $21.41 a share - Stock Titan
Gilead Sciences Inc and Arcus Biosciences Inc Post ARC-7 Plenary Q&A Transcript - GuruFocus
Arcus Biosciences, Inc. Files Form 8-K with SEC for Common Stock Listed on NYSE (RCUS) - Minichart
Arcus Biosciences, Inc. Announces Resignation of Jennifer Jarrett as Chief Operating Officer, Effective March 30, 2026 - marketscreener.com
Arcus Biosciences Announces COO Resignation and Transition Plan - TipRanks
Arcus Biosciences chief operating officer Jennifer Jarrett to resign March 30 - Investing.com Australia
Arcus Biosciences' Jennifer Jarrett to Resign as COO, Effective March 30, 2026 - TradingView
Arcus Biosciences chief operating officer Jennifer Jarrett to resign March 30 By Investing.com - Investing.com South Africa
Arcus Biosciences COO Jennifer Jarrett to resign March 30 - StreetInsider
COO Jennifer Jarrett to exit Arcus Biosciences (RCUS), stay on as advisor - Stock Titan
Aug Setups: Can Arcus Biosciences Inc stock double in the next year2026 Earnings & Real-Time Buy Signal Alerts - baoquankhu1.vn
Hudson Bay Capital Management LP Has $4.62 Million Stake in Arcus Biosciences, Inc. $RCUS - MarketBeat
RCUS PE Ratio & Valuation, Is RCUS Overvalued - Intellectia AI
(RCUS) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Arcus Biosciences, Inc. (RCUS) Stock Price History & Data - Traders Union
B of A Securities Maintains Arcus Biosciences (RCUS) Neutral Recommendation - MSN
Arcus Biosciences, Inc. $RCUS Shares Bought by Decheng Capital LLC - MarketBeat
Here’s what analysts think about Arcus Biosciences (RCUS) - MSN
WINTON GROUP Ltd Purchases Shares of 92,229 Arcus Biosciences, Inc. $RCUS - MarketBeat
Why Arcus Biosciences (RCUS) Is Up 9.5% After New Casdatifan Data And Pipeline Expansion - simplywall.st
Arcus Biosciences (RCUS) Valuation After Casdatifan Kidney Cancer Data Pipeline Update And Earnings - Sahm
How (RCUS) Movements Inform Risk Allocation Models - Stock Traders Daily
New Arcus Biosciences hires receive stock options at $23.43 - Stock Titan
Arcus Biosciences at Leerink Conference: Casdatifan’s Promising Data By Investing.com - Investing.com Canada
RCUS: Casdatifan delivers higher efficacy and durable responses in RCC, with strong upcoming trial data - TradingView
Is Arcus Biosciences Inc still a buy after recent gainsWeekly Trading Summary & Comprehensive Market Scan Insights - baoquankhu1.vn
Performance Recap: Can Arcus Biosciences Inc disrupt its industryJuly 2025 Macro Moves & Scalable Portfolio Growth Methods - baoquankhu1.vn
Vanguard Group Inc. Increases Stock Holdings in Arcus Biosciences, Inc. $RCUS - MarketBeat
Aug Sectors: Is Arcus Biosciences Inc in a long term uptrendQuarterly Performance Summary & Free High Return Stock Watch Alerts - baoquankhu1.vn
Citigroup Raises Arcus Biosciences (RCUS) Price Target to $45 | - GuruFocus
Citigroup Raises Arcus Biosciences (NYSE:RCUS) Price Target to $45.00 - MarketBeat
Fisher Asset Management LLC Acquires 640,990 Shares of Arcus Biosciences, Inc. $RCUS - MarketBeat
RCUS SEC FilingsArcus Bioscience 10-K, 10-Q, 8-K Forms - Stock Titan
Arcus (RCUS) Q4 2025 Earnings Call Transcript - AOL.com
Finanzdaten der Arcus Biosciences Inc-Aktie (RCUS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):